Family & Community Medicine
Medical Director, UMMC Addiction Treatment Programs at 1001 West Pratt Street; Associate Director, University of Maryland Medical Center Addiction Medicine Fellowship
Education and Training
BA magna cum laude with honors in History, Yale University, New Haven, CT
Postbaccalaureate Premedical Program, Goucher College, Baltimore, MD
MD, University of Pennsylvania School of Medicine, Philadelphia, PA
Residency, Family Medicine, Santa Rosa Family Medicine Residency Program (UCSF Affiliate)
Fellowship, Addiction Medicine, University of Maryland Medical Center, Baltimore, MD
I have been a faculty member at the University of Maryland School of Medicine since completing my fellowship in Addiction Medicine in 2015. Now full-time, I divide my clinical responsibilities between the Division of Addiction Research and Treatment (DART) in the Department of Psychiatry and the Department of Family and Community Medicine. As medical director of the UMMC Addiction Treatment Programs at 1001 West Pratt Street, , I treat patients, coordinate clinical care, host research projects, and participate in the clinical education of medical students, psychiatry residents, and addiction fellows. We are working to further the integration of medical and mental health services in the substance use disorder treatment setting. In addition, as the associate director of the Addiction Medicine Fellowship, I collaborate in fellow recruiting, program accreditation, and educational seminars.
In the Department of Family and Community Medicine, I precept medical students and residents in their training. In addition, I am undertaking writing and curriculum development, especially in domains that relate to the intersection of primary care, care of chronic illness in patients with addiction, and enhanced treatment of substance use disorders.
primary care, addiction, substance use disorders, opioid use disorders, reverse colocation, family medicine, smoking cessation
1. Weintraub E, Greenblatt AD, Chang J, Himelhoch S, Welsh C. Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. Am J Addict. 2018 Dec;27(8):612-617. doi: 10.1111/ajad.12805.
2. Visconti AJ, Sell J, Greenblatt AD. Primary Care for Persons Who Inject Drugs. Am Fam Physician. 2019 Jan 15;99(2):109-116.
3. Cai NS, Quiroz C, Bonaventura J, Bonifazi A, Cole TO, Purks J, Billing AS, Massey E, Wagner M, Wish ED, Guitart X, Rea W, Lam S, Moreno E, Casadó-Anguera V, Greenblatt AD, Jacobson AE, Rice KC, Casadó V, Newman AH, Winkelman JW, Michaelides M, Weintraub E, Volkow ND, Belcher AM, Ferré S (2019). J Clin Invest. 2019 Mar 26;130. pii: 126912. doi: 10.1172/JCI126912. Complexes of mu-opioid and galanin receptors determine the dopaminergic effects of opioids.
4. Belcher AM, Cole TO, Greenblatt AD, Hoag SW, Epstein DH, Wagner M, Billing AS, Massey E, Hamilton KR, Kozak Z, Welsh CJ, Weintraub E, Wickwire EM, Wish ED, Kaptchuk TJ, Colloca L. Open-label dose-extending placebos for opioid use disorder: A protocol for a randomized controlled clinical trial with methadone treatment. BMJ Open. 2019 Jun 21;9(6):e026604. doi: 10.1136/bmjopen-2018-026604.
Diplomate, American Board of Family Medicine
Diplomate, American Board of Preventive Medicine: Addiction Medicine
Fellow, American Society of Addiction Medicine